Topic: neurodegenerative diseases
Swedish researchers have found that the rogue SOD1 protein can “transmit” protein misfolding in ALS.
The deal follows a midphase trial that linked oral myeloperoxidase inhibitor AZD3241 to numerical improvements on a scale of MSA symptoms.
Blocking the interaction between pathological tau proteins and the nuclear membrane of neurons could represent a new approach to Alzheimer's, a new study finds.
Gene therapy specialist RegenXBio has added another program to its pipeline, going after Batten disease variant CLN2.
Soluble toll-like receptors could hold promise in reversing amyloid plaques.
Scrutinizing a newly discovered neuron could help guide efforts to find treatments for neurological diseases.
Males of soybean cyst nematode, or H. glycines, are able reverse neurodegeneration as part of their natural life cycle.
MD Anderson and Accelerator Life Science Partners unveiled Magnolia Neurosciences, to develop neuroprotective drugs with a $31 million series A.
PARP inhibitors prevent the misplacement of a specific protein that has been implicated in ALS, new research shows.
The brain's lymphatic vessels might play a critical role in Alzheimer's and could be a new target for treatment.